Gregory Gene Freitag - Net Worth and Insider Trading

Gregory Gene Freitag Net Worth

The estimated net worth of Gregory Gene Freitag is at least $2 Million dollars as of 2024-05-12. Gregory Gene Freitag is the Director of Axogen Inc and owns about 271,594 shares of Axogen Inc (AXGN) stock worth over $2 Million. Gregory Gene Freitag is also the Director of PDS Biotechnology Corp and owns about 46,153 shares of PDS Biotechnology Corp (PDSB) stock worth over $161,997. Details can be seen in Gregory Gene Freitag's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Gregory Gene Freitag has not made any transactions after 2024-03-07 and currently still holds the listed stock(s).

Transaction Summary of Gregory Gene Freitag

To

Gregory Gene Freitag Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gregory Gene Freitag owns 4 companies in total, including Axogen Inc (AXGN) , PDS Biotechnology Corp (PDSB) , and Pressure BioSciences Inc (PBIO) among others .

Click here to see the complete history of Gregory Gene Freitag’s form 4 insider trades.

Insider Ownership Summary of Gregory Gene Freitag

Ticker Comapny Transaction Date Type of Owner
AXGN Axogen Inc 2024-03-07 director
PDSB PDS Biotechnology Corp 2021-06-15 director
PBIO Pressure BioSciences Inc 2010-07-27 director
2023-01-05 director

Gregory Gene Freitag Latest Holdings Summary

Gregory Gene Freitag currently owns a total of 2 stocks. Among these stocks, Gregory Gene Freitag owns 271,594 shares of Axogen Inc (AXGN) as of March 7, 2024, with a value of $2 Million and a weighting of 90.6%. Gregory Gene Freitag also owns 46,153 shares of PDS Biotechnology Corp (PDSB) as of June 15, 2021, with a value of $161,997 and a weighting of 9.4%.

Latest Holdings of Gregory Gene Freitag

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AXGN Axogen Inc 2024-03-07 271,594 5.75 1,561,666
PDSB PDS Biotechnology Corp 2021-06-15 46,153 3.51 161,997

Holding Weightings of Gregory Gene Freitag


Gregory Gene Freitag Form 4 Trading Tracker

According to the SEC Form 4 filings, Gregory Gene Freitag has made a total of 10 transactions in Axogen Inc (AXGN) over the past 5 years, including 0 buys and 10 sells. The most-recent trade in Axogen Inc is the sale of 25,000 shares on March 7, 2024, which brought Gregory Gene Freitag around $225,000.

According to the SEC Form 4 filings, Gregory Gene Freitag has made a total of 1 transactions in PDS Biotechnology Corp (PDSB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in PDS Biotechnology Corp is the acquisition of 5,882 shares on June 15, 2021, which cost Gregory Gene Freitag around $49,997.

Insider Trading History of Gregory Gene Freitag

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gregory Gene Freitag Trading Performance

GuruFocus tracks the stock performance after each of Gregory Gene Freitag's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gregory Gene Freitag is 32.51%. GuruFocus also compares Gregory Gene Freitag's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gregory Gene Freitag within 3 months outperforms 3 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Gregory Gene Freitag's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Gregory Gene Freitag

Average Return

Average return per transaction

Outperforming Transactions

1 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 22.39
Relative Return to S&P 500(%) 20.39

Gregory Gene Freitag Ownership Network

Ownership Network List of Gregory Gene Freitag

No Data

Ownership Network Relation of Gregory Gene Freitag


Gregory Gene Freitag Owned Company Details

What does Axogen Inc do?

Who are the key executives at Axogen Inc?

Gregory Gene Freitag is the director of Axogen Inc. Other key executives at Axogen Inc include Chief R&D Officer Angelo Scopelianos , director & CEO Karen L. Zaderej , and VP & Clinical&Translational Sc Erick Wayne Devinney .

Axogen Inc (AXGN) Insider Trades Summary

Over the past 18 months, Gregory Gene Freitag made 4 insider transaction in Axogen Inc (AXGN) with a net sale of 87,448. Other recent insider transactions involving Axogen Inc (AXGN) include a net sale of 128,948 shares made by Peter J Mariani , a net sale of 42,343 shares made by Michael Patrick Donovan , and a net sale of 39,280 shares made by Karen L. Zaderej .

In summary, during the past 3 months, insiders sold 118,082 shares of Axogen Inc (AXGN) in total and bought 0 shares, with a net sale of 118,082 shares. During the past 18 months, 309,478 shares of Axogen Inc (AXGN) were sold and 30,000 shares were bought by its insiders, resulting in a net sale of 279,478 shares.

Axogen Inc (AXGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Axogen Inc Insider Transactions

No Available Data

Gregory Gene Freitag Mailing Address

Above is the net worth, insider trading, and ownership report for Gregory Gene Freitag. You might contact Gregory Gene Freitag via mailing address: 13631 Progress Blvd., Alachua Fl 32615.

Discussions on Gregory Gene Freitag

No discussions yet.